Time to end the war on cell therapy

10.1002/ejhf.1700

10.1093/eurheartj/ehv136

10.1161/CIRCRESAHA.118.311217

10.1161/CIRCRESAHA.118.313251

10.1001/jama.2012.25321

10.1016/j.ahj.2014.03.022

10.1001/jama.2013.282909

10.1016/S0140-6736(16)30137-4

10.1016/j.jacc.2016.11.009

10.1161/CIRCRESAHA.117.311827

10.1161/CIRCULATIONAHA.106.687376

10.1001/jama.2009.685

10.1161/CIRCRESAHA.111.245993

10.1016/j.jcin.2016.05.003

10.1016/j.ahj.2011.01.028

10.1016/j.jacc.2013.09.014

10.1001/jama.2012.418

10.1038/nbt.3857

10.1161/CIRCRESAHA.117.311987

10.1093/eurheartj/ehx764

10.1161/CIRCRESAHA.115.308056

10.1016/S0140-6736(19)30542-2

10.1161/CIRCRESAHA.113.300219

10.1161/CIRCRESAHA.117.310710

10.1093/eurheartj/ehx248

10.1093/eurheartj/ehw640

U.S. Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb M.D. on the FDA's new policy steps and enforcement efforts to ensure proper oversight of stem cell therapies and regenerative medicine.https://www.fda.gov/news‐events/press‐announcements/statement‐fda‐commissioner‐scott‐gottlieb‐md‐fdas‐new‐policy‐steps‐and‐enforcement‐efforts‐ensure(17 February 2020).